GlassScriptPhysician profile
Hunter K Huston
NPI 1861751703
$8,610.87
in general payments reported to CMS, 2019-2025
14 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $56.06 · 2021: $84.99 · 2022: $5,551 · 2023: $573 · 2024: $1,622 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,937 · Food and Beverage: $294 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,937.00 |
| Food and Beverage | $294.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,673.42 | 2019-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $308.97 | 2019-2020 | |
| Outset Medical INC | $158.12 | 2024-2025 | |
| Nxstage Medical, INC. | $118.44 | 2023 | Nxstage System One, Liberty Select Cycler |
| Alexion Pharmaceuticals, INC. | $105.73 | 2019-2022 | |
| Amgen INC. | $82.48 | 2019-2020 | |
| Pfizer INC. | $32.34 | 2019 | |
| Fresenius USA Marketing, INC. | $29.46 | 2019 | |
| Vifor Pharma, INC. | $27.64 | 2019 | |
| Opko Pharmaceuticals, LLC | $23.69 | 2019 | |
| Daiichi Sankyo INC. | $16.51 | 2019 | |
| Biomerieux INC | $13.62 | 2019 | |
| Mallinckrodt Enterprises LLC | $10.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $9.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Huston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.